NasdaqGS:RXRXBiotechs
Recursion’s First Clinical Signal And Sanofi Milestone Test AI Drug Thesis
Recursion Pharmaceuticals reported its first positive clinical proof-of-concept for REC-4881 in familial adenomatous polyposis.
The company hit a fifth collaboration milestone with Sanofi tied to its AI driven drug discovery platform.
Management extended the cash runway into early 2028, reinforcing funding visibility for ongoing programs.
For investors watching NasdaqGS:RXRX, this mix of clinical and partnership progress comes alongside a share price of $3.67 and a 1-year return...